

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(10) International Publication Number

WO 2017/123593 A1

(43) International Publication Date

20 July 2017 (20.07.2017)

(51) International Patent Classification:

A61K 31/397 (2006.01) *A61K 35/14* (2015.01)
A61K 9/08 (2006.01) *A61P 35/00* (2006.01)

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(21) International Application Number:

PCT/US2017/012948

(22) International Filing Date:

11 January 2017 (11.01.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/277,236 11 January 2016 (11.01.2016) US

(71) Applicant: EPICENTRX, INC. [US/US]; 800 W. El Camino Real, Suite 180, Mountain View, CA 94040 (US).

(72) Inventors: ORONSKY, Bryan, T.; 28540 Matadero Creek Lane, Los Altos Hills, CA 94022 (US). SCICINSKI, Jan; 19546 Vineyard Lane, Saratoga, CA 95070 (US). CAROEN, Scott; 680 Mission Street, Apt. 30P, San Francisco, CA 94105 (US).

(74) Agents: DAVIS, Chad, E. et al.; Goodwin Procter LLP, 100 Northern Avenue, Boston, MA 02210 (US).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))



WO 2017/123593 A1

(54) Title: COMPOSITIONS AND METHODS FOR INTRAVENOUS ADMINISTRATION OF 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHANONE

(57) Abstract: The invention provides compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone (ABDNAZ), including formulations containing autologous whole blood and ABDNAZ that can be rapidly administered to a patient by intravenous infusion without any significant pain at the site of infusion.

COMPOSITIONS AND METHODS FOR INTRAVENOUS ADMINISTRATION OF 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHANONE

CROSS REFERENCE TO RELATED APPLICATION

5 [0001] This application claims the benefit of and priority to United States Provisional Patent Application serial number 62/277,236, filed January 11, 2016, the contents of which are hereby incorporated by reference.

FIELD OF THE INVENTION

10 [0002] The invention provides compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone (ABDNAZ), including formulations containing autologous whole blood and ABDNAZ that can be rapidly administered to a patient by intravenous infusion without any significant pain at the site of infusion.

BACKGROUND


15 [0003] Cancer is a significant health problem despite the many advances made for detecting and treating this disease. Leading types of cancer afflicting substantial numbers of patients include prostate cancer, breast cancer, and lung cancer. Prostate cancer is the most common form of cancer among males, with an estimated incidence of 30% in men over the age of 50. Moreover, clinical evidence indicates that human prostate cancer has the propensity to metastasize to bone, and the disease appears to progress inevitably from androgen dependent to androgen refractory 20 status, leading to increased patient mortality. Breast cancer remains a leading cause of death in women. Its cumulative risk is relatively high; certain reports indicate that approximately one in eight women are expected to develop some type of breast cancer by age 85 in the United States. Likewise, lung cancer is a leading cause of cancer-related death, and non-small cell lung cancer (NSCLC) accounts for about 80% of these cases.

[0004] Treatment options for cancer patients often include surgery, radiotherapy, chemotherapy, hormone therapy, or a combination thereof. The compound ABDNAZ described in, for example, U.S. Patent Nos. 7,507,842; 8,299,053; and 8,927,527 has been studied in multiple clinical trials for use in treating cancer. ABDNAZ is typically formulated as a mixture with water, 5 dimethylacetamide, and a poly(ethylene glycol) for intravenous infusion to the patient suffering from cancer. In clinical trials, patients receiving the aforementioned mixture of ABDNAZ by intravenous infusion have complained of significant pain at the site of infusion due to the ABDNAZ mixture. The significant pain at the site of infusion due to the ABDNAZ mixture has required medical personnel to reduce the rate at which the ABDNAZ mixture is administered to 10 the patient, sometimes requiring infusion times up to eight hours. The long infusion times and slow rate of administration has, in some instances, limited the amount of ABDNAZ that can be administered to a patient when the ABDNAZ is used in combination with radiation therapy to be performed the same day as administration of ABDNAZ.

[0005] The present invention provides a new formulation containing ABDNAZ that can be rapidly administered to the patient without causing any significant pain at the site of infusion and has other advantages as described herein below.

SUMMARY

[0006] The invention provides compositions and methods for intravenous administration of 2- 15 bromo-1-(3,3-dinitroazetidin-1-yl)ethanone (ABDNAZ), including formulations containing autologous whole blood and ABDNAZ that can be rapidly administered to a patient by intravenous infusion. The compositions and methods provide the further advantage that rapid administration of the formulation does not result in any significant pain at the site of intravenous infusion due to the administration. The compound ABDNAZ has the following chemical structure:



20

[0007] The ABDNAZ formulations contain whole blood (preferably autologous whole blood), ABDNAZ, and an anticoagulant. The formulations and methods are particularly useful for

administering ABDNAZ to a patient suffering from cancer. The ABDNAZ formulations can be administered intravenously to the patient at a rate of, for example, at least 5 mL/hour, 10 mL/hour, 30 mL/hour, or higher rates. The rapid rate of administration reduces the time required to administer a therapeutically effective amount of ABDNAZ for treating cancer, and has particular 5 advantages when large doses of ABDNAZ need to be administered to the patient during the same day as the patient receives radiation therapy. The methods can be further characterized according to the magnitude of pain experienced by the patient at the site of administering the ABDNAZ formulation, wherein the magnitude of any pain experienced by the patient is small. The invention having been generally described is explained in more detail in the aspects and embodiments below 10 and in the detailed description.

[0008] One aspect of the invention provides a method for intravenous administration of an ABDNAZ formulation to a patient suffering from cancer in order to treat the cancer. The method comprises intravenously administering to the patient in need thereof a therapeutically effective amount of an ABDNAZ formulation described herein (such as a formulation comprising whole 15 blood, ABDNAZ, and an anticoagulant) in order to treat the cancer. The ABDNAZ formulation may be administered at a rate of, for example, at least 5 mL/hour or at least 10 mL/hour. The method provides the advantage of being able to rapidly administer ABDNAZ without causing undue pain at the site of administering the ABDNAZ formulation, and any such pain may be characterized according to, for example, the feature that any such pain is no greater than Grade 1 20 pain.

[0009] Another aspect of the invention provides a method for rapid intravenous administration of an ABDNAZ formulation to a patient while minimizing injection site pain experienced by the patient, wherein the method comprises intravenously administering to the patient at a rate of, for example, at least 10 mL/hour, an ABDNAZ formulation described herein (such as a formulation 25 comprising whole blood, ABDNAZ, and an anticoagulant), wherein any pain experienced by the patient at the site of intravenous administration of the ABDNAZ formulation due to intravenous administration of the ABDNAZ formulation is no greater than Grade 2. The ABDNAZ formulation may be further characterized according to the concentration of ABDNAZ in the

formulation, such as where the formulation contains ABDNAZ at a concentration of, for example, at least 10 $\mu\text{g}/\text{mL}$, at least 20 $\mu\text{g}/\text{mL}$, at least 50 $\mu\text{g}/\text{mL}$, at least 100 $\mu\text{g}/\text{mL}$, or at least 150 $\mu\text{g}/\text{mL}$.

[0010] Another aspect of the invention provides an intravenous formulation containing ABDNAZ for intravenous administration to a patient, wherein the formulation comprises: (a) 5 whole blood in an amount of at least 60% v/v of the formulation; (b) a polyethylene glycol at a concentration of from about 0.4 $\mu\text{L}/\text{mL}$ to about 30 $\mu\text{L}/\text{mL}$ in the formulation; (c) N,N-dimethylacetamide at a concentration of from about 0.2 $\mu\text{L}/\text{mL}$ to about 15 $\mu\text{L}/\text{mL}$ in the formulation; (d) ABDNAZ at a concentration of at least 10 $\mu\text{g}/\text{mL}$ in the formulation; (e) water; and (f) an anticoagulant. The intravenous formulations are suited for use in the methods described 10 herein, and provide the advantage of being able to be rapidly administered to the patient by intravenous infusion without causing any significant pain at the site of administration.

[0011] Another aspect of the invention provides a kit for intravenous administration of an ABDNAZ formulation to a patient suffering from cancer in order to treat the cancer. The kit comprises: (i) a formulation comprising ABDNAZ, and (ii) instructions for intravenous 15 administration of an ABDNAZ formulation to a patient suffering from cancer in order to treat the cancer according to procedures described herein. One benefit of the kit is that it provides an ABDNAZ formulation capable of being rapidly administered to the patient by intravenous infusion without causing any significant pain at the site of administration.

[0012] Another aspect of the invention provides a kit for rapid intravenous administration of 20 an ABDNAZ formulation to a patient while minimizing injection site pain experienced by the patient. The kit comprises: (i) a formulation comprising ABDNAZ, and (ii) instructions for rapid intravenous administration of an ABDNAZ formulation to a patient while minimizing injection site pain experienced by the patient according to procedures described herein.

DETAILED DESCRIPTION

25 [0013] The invention provides compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone (ABDNAZ), including formulations containing autologous whole blood and ABDNAZ that can be rapidly administered to a patient by intravenous

infusion. The compositions and methods provide the further advantage that rapid administration of the formulation does not result in any significant pain at the site of intravenous infusion due to the administration.

[0014] The ABDNAZ formulations contain whole blood (preferably autologous whole blood), 5 ABDNAZ, and an anticoagulant. The formulations and methods are particularly useful for administering ABDNAZ to a patient suffering from cancer. The ABDNAZ formulations can be administered intravenously to the patient at a rate of, for example, at least 5 mL/hour, 10 mL/hour, 30 mL/hour, or a higher rate. The rapid rate of administration reduces the time required to administer a therapeutically effective amount of ABDNAZ for treating cancer, and has particular 10 advantages when large doses of ABDNAZ need to be administered to the patient during the same day as the patient receives radiation therapy. The methods can be further characterized according to the magnitude of pain experienced by the patient at the site of administering the ABDNAZ formulation, wherein the magnitude of any pain experienced by the patient is small. Various 15 aspects of the invention are set forth below in sections; however, aspects of the invention described in one particular section are not to be limited to any particular section.

I. THERAPEUTIC METHODS

[0015] The invention provides methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone (ABDNAZ). The methods enable more rapid administration of ABDNAZ to a patient and avoid any substantial pain at the site of administration due to the 20 ABDNAZ. Various features of the methods are described in sections below. The sections are arranged for convenience and information in one section is not limited to that section, but may be applied to other sections.

First Method

[0016] One aspect of the invention provides a method for intravenous administration of an 25 ABDNAZ formulation to a patient suffering from cancer in order to treat the cancer. The method comprises intravenously administering to the patient in need thereof a therapeutically effective amount of an ABDNAZ formulation comprising whole blood, ABDNAZ, and an anticoagulant, in order to treat the cancer. The whole blood is preferably autologous whole blood.

[0017] The method may be further characterized according to the rate at which the ABDNAZ formulation is intravenously administered to the patient. In certain embodiments, the ABDNAZ formulation is intravenously administered to the patient at a rate of at least 3 mL/hour. In certain embodiments, the ABDNAZ formulation is intravenously administered to the patient at a rate of at least 5 mL/hour. In certain embodiments, wherein the ABDNAZ formulation is intravenously administered to the patient at a rate of at least 10 mL/hour.

[0018] One benefit of the above method is that it substantially reduces the amount of pain experienced by the patient at the site of administering ABDNAZ. Accordingly, in certain embodiments, the method is characterized by the feature that any pain experienced by the patient at the site of intravenous administration of the ABDNAZ formulation due to intravenous administration of the ABDNAZ formulation is no greater than Grade 2. In certain other embodiments, any pain experienced by the patient at the site of intravenous administration of the ABDNAZ formulation due to intravenous administration of the ABDNAZ formulation is no greater than Grade 1.

15 **Second Method**

[0019] Another aspect of the invention provides a method for intravenous administration of an ABDNAZ formulation to a patient while minimizing injection site pain experienced by the patient. The method comprises intravenously administering to the patient at a rate of at least 3 mL/hour an ABDNAZ formulation comprising whole blood, ABDNAZ, and an anticoagulant, wherein any pain experienced by the patient at the site of intravenous administration of the ABDNAZ formulation due to intravenous administration of the ABDNAZ formulation is no greater than Grade 2. In certain embodiments, the ABDNAZ formulation is intravenously administered to the patient at a rate of at least 5 mL/hour.

Third Method

25 [0020] Another aspect of the invention provides a method for rapid intravenous administration of an ABDNAZ formulation to a patient while minimizing injection site pain experienced by the patient. The method comprises intravenously administering to the patient at a rate of at least 10 mL/hour an ABDNAZ formulation comprising whole blood, ABDNAZ, and an anticoagulant,

wherein any pain experienced by the patient at the site of intravenous administration of the ABDNAZ formulation due to intravenous administration of the ABDNAZ formulation is no greater than Grade 2.

[0021] One benefit of the above method is that it substantially reduces the amount of pain experienced by the patient at the site of administering ABDNAZ. Accordingly, in certain embodiments, the method is characterized by the feature that any pain experienced by the patient at the site of intravenous administration of the ABDNAZ formulation due to intravenous administration of the ABDNAZ formulation is no greater than Grade 1.

[0022] In certain embodiments, the patient is suffering from cancer.

10 **Fourth Method**

[0023] Another aspect of the invention provides a method for intravenous administration of an ABDNAZ formulation to a patient while minimizing injection site pain experienced by the patient. The method comprises intravenously administering to the patient at a rate of at least 3 mL/hour an ABDNAZ formulation comprising ABDNAZ, an anticoagulant, and a blood product selected from 15 the group consisting of an erythrocyte cell, blood plasma, and whole blood. The method may be further characterized according to the feature that any pain experienced by the patient at the site of intravenous administration of the ABDNAZ formulation due to intravenous administration of the ABDNAZ formulation is no greater than Grade 2. In certain embodiments, the ABDNAZ formulation is intravenously administered to the patient at a rate of at least 5 mL/hour, or at least 20 10 mL/hour. In certain embodiments, the blood product is an erythrocyte cell. In certain embodiments, the ABDNAZ formulation comprises a population of erythrocyte cells, such as where the ABDNAZ formulation comprises erythrocyte cells in an amount of at least about 2%, 5%, 8%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, or 45% by volume of the ABDNAZ formulation.

Exemplary Features of the First, Second, Third, and Fourth Methods

[0024] The above methods may be further characterized by additional features, such as the rate of infusion of the ABDNAZ formulation, the concentration of ABDNAZ in the ABDNAZ formulation, the identity of components in the ABDNAZ formulation, the amount of whole blood

in the ABDNAZ formulation, the volume of ABDNAZ formulation administered to patient, and other features as described in more detail below.

Rate of Infusion of ABDNAZ Formulation

[0025] The method may be further characterized according to the rate at which the ABDNAZ formulation is administered to the patient. Accordingly, in certain embodiments, the ABDNAZ formulation is intravenously administered to the patient at a rate of at least 30 mL/hour. In certain embodiments, the ABDNAZ formulation is intravenously administered to the patient at a rate of at least 60 mL/hour. In certain embodiments, the ABDNAZ formulation is intravenously administered to the patient at a rate of at least 90 mL/hour. In certain embodiments, the ABDNAZ formulation is intravenously administered to the patient at a rate of at least 120 mL/hour. In yet other embodiments, the ABDNAZ formulation is intravenously administered to the patient at a rate of at least 150 mL/hour, 180 mL/hour, 210 mL/hour, 240 mL/hour, 270 mL/hour, 300 mL/hour, 330 mL/hour, or 360 mL/hour. In yet other embodiments, the ABDNAZ formulation is intravenously administered to the patient at a rate in the range of from about 100 mL/hour to about 150 mL/hour, from about 150 mL/hour to about 200 mL/hour, from about 180 mL/hour to about 220 mL/hour, from about 200 mL/hour to about 250 mL/hour, from about 250 mL/hour to about 300 mL/hour, from about 275 mL/hour to about 325 mL/hour, or from about 300 mL/hour to about 350 mL/hour.

Concentration of ABDNAZ in the ABDNAZ Formulation

[0026] The method may be further characterized according to the concentration of ABDNAZ in the ABNDAZ formulation. Accordingly, in certain embodiments, the ABDNAZ formulation contains ABDNAZ at a concentration of at least 10 μ g/mL. In certain embodiments, the ABDNAZ formulation contains ABDNAZ at a concentration of at least 20 μ g/mL. In certain embodiments, the ABDNAZ formulation contains ABDNAZ at a concentration of at least 50 μ g/mL. In certain embodiments, the ABDNAZ formulation contains ABDNAZ at a concentration of at least 100 μ g/mL. In certain embodiments, the ABDNAZ formulation contains ABDNAZ at a concentration of at least 150 μ g/mL. In certain embodiments, the ABDNAZ formulation contains ABDNAZ at a concentration in the range of about 10 μ g/mL to about 1 mg/mL. In certain

embodiments, the ABDNAZ formulation contains ABDNAZ at a concentration in the range of about 10 μ g/mL to about 0.5 mg/mL. In certain embodiments, the ABDNAZ formulation contains ABDNAZ at a concentration in the range of about 10 μ g/mL to about 250 μ g/mL. In certain embodiments, the ABDNAZ formulation contains ABDNAZ at a concentration in the range of about 20 μ g/mL to about 200 μ g/mL. In certain embodiments, the ABDNAZ formulation contains ABDNAZ at a concentration in the range of about 200 μ g/mL to about 750 μ g/mL. In certain embodiments, the ABDNAZ formulation contains ABDNAZ at a concentration in the range of about 200 μ g/mL to about 400 μ g/mL, about 400 μ g/mL to about 600 μ g/mL, about 500 μ g/mL to about 700 μ g/mL, or about 600 μ g/mL to about 700 μ g/mL.

10 **Exemplary More Specific ABDNAZ Formulations**

[0027] Exemplary more specific ABDNAZ formulations that may be used in the methods include, for example, formulations containing whole blood, ABDNAZ, an anticoagulant, and optionally one or more of water, a polyethylene glycol, and N,N-dimethylacetamide. In certain embodiments, the ABDNAZ formulation consists essentially of whole blood, ABDNAZ, and an anticoagulant. In certain embodiments, the ABDNAZ formulation consists of whole blood, ABDNAZ, an anticoagulant, and optionally one or more of water, a polyethylene glycol, and N,N-dimethylacetamide. In certain embodiments, the ABDNAZ formulation consists of whole blood, ABDNAZ, an anticoagulant, and optionally one or more of water, a polyethylene glycol having a number-average molecular weight in the range of about 200 g/mol to about 600 g/mol, and N,N-dimethylacetamide. In certain embodiments, the ABDNAZ formulation consists of whole blood, ABDNAZ, an anticoagulant, water, a polyethylene glycol having a number-average molecular weight in the range of about 200 g/mol to about 600 g/mol, and N,N-dimethylacetamide. In certain embodiments, the ABDNAZ formulation consists of whole blood, ABDNAZ, an anticoagulant, and optionally one or more of water, a polyethylene glycol having a number-average molecular weight of about 400 g/mol, and N,N-dimethylacetamide. In certain embodiments, the ABDNAZ formulation consists of whole blood, ABDNAZ, an anticoagulant, water, a polyethylene glycol having a number-average molecular weight of about 400 g/mol, and N,N-dimethylacetamide.

Anticoagulant

[0028] The method may be further characterized according to the identity and/or amount of the anticoagulant. Accordingly, in certain embodiments, the anticoagulant comprises one or more of heparin and a citrate salt. In certain embodiments, the anticoagulant is a solution comprising an alkali metal citrate salt, dextrose, and water. In certain embodiments, the anticoagulant is present in the ABDNAZ formulation in an amount ranging from about 0.1% wt/wt to about 15% w/w. In certain embodiments, the anticoagulant is present in the ABDNAZ formulation in an amount ranging from about 1% wt/wt to about 10% w/w. In certain embodiments, the anticoagulant is present in the ABDNAZ formulation in an amount ranging from about 2% wt/wt to about 8% w/w.

10 Amount of Whole Blood in the ABDNAZ Formulation

[0029] The method may be further characterized according to the amount of whole blood in the ABDNAZ formulation. Accordingly, in certain embodiments, the whole blood constitutes at least 30% wt/wt of the ABDNAZ formulation. In certain embodiments, the whole blood constitutes at least 40% wt/wt of the ABDNAZ formulation. In certain embodiments, the whole blood constitutes at least 50% wt/wt of the ABDNAZ formulation. In certain embodiments, the whole blood constitutes at least 60% wt/wt of the ABDNAZ formulation. In certain embodiments, the whole blood constitutes at least 75% wt/wt of the ABDNAZ formulation. In certain embodiments, the whole blood constitutes at least 90% wt/wt of the ABDNAZ formulation. In certain embodiments, the whole blood constitutes from about 60% wt/wt to about 99% wt/wt of the ABDNAZ formulation. In certain embodiments, the whole blood constitutes from about 70% wt/wt to about 95% wt/wt of the ABDNAZ formulation. In certain embodiments, the whole blood constitutes from about 75% wt/wt to about 90% wt/wt of the ABDNAZ formulation. In certain embodiments, there is from about 5 mL to about 10 mL of whole blood in the ABDNAZ formulation, from about 10 mL to about 15 mL of whole blood in the ABDNAZ formulation, from about 9 mL to about 11 mL of whole blood in the ABDNAZ formulation, from about 10 mL to about 20 mL of whole blood in the ABDNAZ formulation, from about 20 mL to about 30 mL of whole blood in the ABDNAZ formulation, from about 30 mL to about 50 mL of whole blood in the ABDNAZ formulation, from about 50 mL to about 70 mL of whole blood in the ABDNAZ formulation, or from about 70 mL to about 90 mL of whole blood in the ABDNAZ formulation. In

certain embodiments, there is from about 90 mL to about 110 mL of whole blood in the ABDNAZ formulation. In certain embodiments, there is from about 95 mL to about 105 mL of whole blood in the ABDNAZ formulation. In certain embodiments, there is about 100 mL of whole blood in the ABDNAZ formulation.

5 **Volume of ABDNAZ Formulation Administered to Patient**

[0030] The method may be further characterized according to the volume of ABDNAZ formulation administered to the patient. Accordingly, in certain embodiments, the ABDNAZ formulation has a volume in the range of about 10 mL to about 200 mL. In certain embodiments, the ABDNAZ formulation has a volume in the range of about 10 mL to about 15 mL, about 15 mL to about 20 mL, about 20 mL to about 30 mL, or about 30 mL to about 50 mL. In certain embodiments, the ABDNAZ formulation has a volume in the range of about 50 mL to about 200 mL. In certain embodiments, the ABDNAZ formulation has a volume in the range of about 75 mL to about 150 mL. In certain embodiments, the ABDNAZ formulation has a volume in the range of about 90 mL to about 140 mL. In certain embodiments, the ABDNAZ formulation has a volume in the range of about 100 mL to about 140 mL. In certain embodiments, the ABDNAZ formulation has a volume in the range of about 100 mL to about 120 mL.

Timeline for Administering ABDNAZ Formulation

[0031] The method may be further characterized according to the timeline for administering the ABDNAZ formulation to the patient. Accordingly, in certain embodiments, intravenous administration of the ABDNAZ formulation commences within about 1 hour after formation of the ABDNAZ formulation. In certain embodiments, intravenous administration of the ABDNAZ formulation commences within about 30 minutes after formation of the ABDNAZ formulation. In certain embodiments, intravenous administration of the ABDNAZ formulation commences within about 20 minutes after formation of the ABDNAZ formulation. In certain embodiments, intravenous administration of the ABDNAZ formulation is complete within about 6 hours after formation of the ABDNAZ formulation. In certain embodiments, intravenous administration of the ABDNAZ formulation is complete within about 4 hours after formation of the ABDNAZ formulation.

Obtaining Whole Blood for ABDNAZ Formulation

[0032] The method may optionally further comprise obtaining an aliquot of whole blood from the patient, and then using said aliquot to prepare the ABDNAZ formulation for administration to the patient.

5 Location of Intravenous Administration

[0033] The method may be further characterized according to the location of intravenous administration to the patient. In certain embodiments, the intravenous administration is central intravenous administration. In certain embodiments, the intravenous administration is peripheral intravenous administration.

10 Dose of ABDNAZ Administered

[0034] Exemplary dosing amounts of ABDNAZ are provided according to the number of milligrams of ABDNAZ to be administered to the patient based on the surface area of the patient as measured in m^2 . In certain embodiments, the dose ABDNAZ administered to the patient is from about 1 mg/m^2 to about 2 mg/m^2 , about 2 mg/m^2 to about 4 mg/m^2 , about 4 mg/m^2 to about 6 mg/m^2 , about 6 mg/m^2 to about 8 mg/m^2 , about 8 mg/m^2 to about 10 mg/m^2 , about 10 mg/m^2 to about 12 mg/m^2 , about 12 mg/m^2 to about 14 mg/m^2 , about 14 mg/m^2 to about 16 mg/m^2 , about 16 mg/m^2 to about 18 mg/m^2 , about 18 mg/m^2 to about 20 mg/m^2 , about 20 mg/m^2 to about 25 mg/m^2 , about 25 mg/m^2 to about 30 mg/m^2 , about 30 mg/m^2 to about 35 mg/m^2 , about 35 mg/m^2 to about 40 mg/m^2 , about 40 mg/m^2 to about 45 mg/m^2 , about 45 mg/m^2 to about 50 mg/m^2 , about 50 mg/m^2 to about 60 mg/m^2 , or about 60 mg/m^2 to about 75 mg/m^2 .

[0035] The dose of ABDNAZ administered to the patient may be further characterized according to both the amount of ABDNAZ and the mode of delivery, such as intravenous infusion. Accordingly, in certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount ranging from about 1 mg/m^2 to about 90 mg/m^2 . In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount ranging from about 1 mg/m^2 to about 10 mg/m^2 . In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion

providing ABDNAZ in an amount ranging from about 1 mg/m² to about 2.5 mg/m². In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount ranging from about 2.5 mg/m² to about 5 mg/m². In certain embodiments, each dose of the formulation comprising ABDNAZ is 5 administered to the patient by intravenous infusion providing ABDNAZ in an amount ranging from about 5 mg/m² to about 10 mg/m². In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount ranging from about 5 mg/m² to about 7 mg/m². In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion 10 providing ABDNAZ in an amount ranging from about 8 mg/m² to about 9 mg/m². In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount ranging from about 10 mg/m² to about 20 mg/m². In certain embodiments, each dose of the formulation comprising ABDNAZ is 15 administered to the patient by intravenous infusion providing ABDNAZ in an amount ranging from about 1 mg/m² to about 1.5 mg/m², about 1.5 mg/m² to about 2 mg/m², about 2 mg/m² to about 2.5 mg/m², about 2.5 mg/m² to about 3 mg/m², about 3 mg/m² to about 3.5 mg/m², about 3.5 mg/m² to about 4 mg/m², about 4 mg/m² to about 4.5 mg/m², about 4.5 mg/m² to about 5 mg/m², about 5 mg/m² to about 5.5 mg/m², about 5.5 mg/m² to about 6 mg/m², about 6 mg/m² to about 6.5 mg/m², about 6.5 mg/m² to about 7 mg/m², about 7 mg/m² to about 7.5 mg/m², about 7.5 mg/m² to 20 about 8 mg/m², about 8 mg/m² to about 8.5 mg/m², about 8.5 mg/m² to about 9 mg/m², about 9 mg/m² to about 9.5 mg/m², about 9.5 mg/m² to about 10 mg/m², about 10 mg/m² to about 12 mg/m², about 12 mg/m² to about 14 mg/m², about 14 mg/m² to about 16 mg/m², about 16 mg/m² to about 18 mg/m², about 18 mg/m² to about 20 mg/m², about 20 mg/m² to about 25 mg/m², about 25 mg/m² to about 30 mg/m², about 30 mg/m² to about 35 mg/m², about 35 mg/m² to about 40 mg/m², 25 about 40 mg/m² to about 45 mg/m², or about 45 mg/m² to about 50 mg/m². In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount ranging from about 3 mg/m² to about 8 mg/m².

[0036] In more specific embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of about 1.25 mg/m². In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of about 2.5 mg/m². In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of about 5 mg/m². In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of about 8.4 mg/m². In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of about 1 mg/m², about 1.5 mg/m², about 2 mg/m², about 2.5 mg/m², about 3 mg/m², about 3.5 mg/m², about 4 mg/m², about 4.5 mg/m², about 5 mg/m², about 5.5 mg/m², about 6 mg/m², about 6.5 mg/m², about 7 mg/m², about 7.5 mg/m², about 8 mg/m², about 8.5 mg/m², about 9 mg/m², about 9.5 mg/m², about 10 mg/m², about 12 mg/m², about 14 mg/m², about 16 mg/m², about 18 mg/m², about 20 mg/m², about 25 mg/m², about 30 mg/m², about 35 mg/m², about 40 mg/m², about 45 mg/m², or about 50 mg/m².

Extent of any Pain at Site of Intravenous Administration

[0037] The method may be further characterized according to the extent of any pain experienced by the patient at the site of intravenous administration of the ABDNAZ formulation due to intravenous administration of the ABDNAZ formulation. Accordingly, in certain embodiments, any pain experienced by the patient at the site of intravenous administration of the ABDNAZ formulation due to intravenous administration of the ABDNAZ formulation is no greater than Grade 2. In certain other embodiments, any pain experienced by the patient at the site of intravenous administration of the ABDNAZ formulation due to intravenous administration of the ABDNAZ formulation is no greater than Grade 1. The Grade scale for evaluating pain is art-recognized and ranges from 0 to 5, with zero being no pain and five being intense pain. General description of the pain Grades is provided in the table below.

Grade of Pain	General Description
0	No Pain
1	Barely noticeable pain
2	Mild pain
3	Moderate pain
4	Very painful
5	Intense pain that is very difficult to withstand for greater than 5 minutes.

Type of Cancer

[0038] When the ABDNAZ formulation is being administered to a patient suffering from cancer in order to treat the cancer, the method may be further characterized according to type of cancer to be treated. For example, in certain embodiments, the cancer is a solid tumor. In certain embodiments, the cancer is brain cancer, bladder cancer, breast cancer, cervical cancer, 5 cholangiocarcinoma, colon cancer, colorectal cancer, endometrial cancer, esophageal cancer, lung cancer, liver cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, renal cancer, stomach cancer, testicular cancer, or uterine cancer. In certain embodiments, the 10 cancer is brain cancer. In certain embodiments, the cancer is colorectal cancer. In certain embodiments, the cancer is cholangiocarcinoma or lung cancer.

[0039] In certain embodiments, the cancer is lung cancer. In certain embodiments, the lung cancer is small cell lung cancer. In certain other embodiments, the cancer is non-small cell lung cancer. In certain embodiments, the cancer is a leukemia or lymphoma. In certain embodiments, 15 the cancer is a B-cell lymphoma or non-Hodgkin lymphoma.

[0040] Additional exemplary cancers for treatment include, for example, bladder cancer, breast cancer, cervical cancer, colon cancer, colorectal cancer, endometrial cancer, esophageal cancer, leukemia, lung cancer, liver cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, renal cancer, stomach cancer, testicular cancer, and uterine cancer. In yet other 20 embodiments, the cancer is a vascularized tumor, squamous cell carcinoma, adenocarcinoma, small cell carcinoma, melanoma, glioma, neuroblastoma, sarcoma (e.g., an angiosarcoma or

chondrosarcoma), larynx cancer, parotid cancer, biliary tract cancer, thyroid cancer, acral lentiginous melanoma, actinic keratoses, acute lymphocytic leukemia, acute myeloid leukemia, adenoid cystic carcinoma, adenomas, adenosarcoma, adenosquamous carcinoma, anal canal cancer, anal cancer, anorectum cancer, astrocytic tumor, bartholin gland carcinoma, basal cell carcinoma, biliary cancer, bone cancer, bone marrow cancer, bronchial cancer, bronchial gland carcinoma, carcinoid, cholangiocarcinoma, chondrosarcoma, choriod plexus papilloma/carcinoma, chronic lymphocytic leukemia, chronic myeloid leukemia, clear cell carcinoma, connective tissue cancer, cystadenoma, digestive system cancer, duodenum cancer, endocrine system cancer, endodermal sinus tumor, endometrial hyperplasia, endometrial stromal sarcoma, endometrioid adenocarcinoma, endothelial cell cancer, ependymal cancer, epithelial cell cancer, Ewing's sarcoma, eye and orbit cancer, female genital cancer, focal nodular hyperplasia, gallbladder cancer, gastric antrum cancer, gastric fundus cancer, gastrinoma, glioblastoma, glucagonoma, heart cancer, hemangiblastomas, hemangioendothelioma, hemangiomas, hepatic adenoma, hepatic adenomatosis, hepatobiliary cancer, hepatocellular carcinoma, Hodgkin's disease, ileum cancer, 10 insulinoma, intaepithelial neoplasia, interepithelial squamous cell neoplasia, intrahepatic bile duct cancer, invasive squamous cell carcinoma, jejunum cancer, joint cancer, Kaposi's sarcoma, pelvic cancer, large cell carcinoma, large intestine cancer, leiomyosarcoma, lentigo maligna melanomas, lymphoma, male genital cancer, malignant melanoma, malignant mesothelial tumors, medulloblastoma, medulloepithelioma, meningeal cancer, mesothelial cancer, metastatic carcinoma, mouth cancer, mucoepidermoid carcinoma, multiple myeloma, muscle cancer, nasal tract cancer, nervous system cancer, neuroepithelial adenocarcinoma nodular melanoma, non-epithelial skin cancer, non-Hodgkin's lymphoma, oat cell carcinoma, oligodendroglial cancer, oral cavity cancer, osteosarcoma, papillary serous adenocarcinoma, penile cancer, pharynx cancer, pituitary tumors, plasmacytoma, pseudosarcoma, pulmonary blastoma, rectal cancer, renal cell carcinoma, respiratory system cancer, retinoblastoma, rhabdomyosarcoma, sarcoma, serous carcinoma, sinus cancer, skin cancer, small cell carcinoma, small intestine cancer, smooth muscle cancer, soft tissue cancer, somatostatin-secreting tumor, spine cancer, squamous cell carcinoma, striated muscle cancer, submesothelial cancer, superficial spreading melanoma, T cell leukemia, tongue cancer, undifferentiated carcinoma, ureter cancer, urethra cancer, urinary bladder cancer, 20 urinary system cancer, uterine cervix cancer, uterine corpus cancer, uveal melanoma, vaginal carcinoma, vulva cancer, and Wilms' tumor.

25

30

cancer, verrucous carcinoma, VIPoma, vulva cancer, well differentiated carcinoma, or Wilms tumor.

Characterization of Anti-Cancer Effects

[0041] When the ABDNAZ formulation is being administered to a cancer patient in order to treat the cancer, the therapeutic method may be further characterized according to the anti-cancer effect of the treatment, such as (i) a reduction in the size of at least one tumor in the patient, and/or (ii) reduction in the number of tumors in the patient.

[0042] Accordingly, in certain embodiments, the therapeutic method is characterized by at least a 20% reduction in the size of at least one tumor in the patient. In certain other embodiments, there is at least a 35% reduction in the size of at least one tumor in the patient. In certain other embodiments, there is at least a 50% reduction in the size of at least one tumor in the patient. In certain other embodiments, there is at least a 60%, 70%, 80% or 90% reduction in the size of at least one tumor in the patient. In certain other embodiments, there is about a 5%-50%, 10%-50%, 20%-50%, 5%-75%, 10%-75%, 20%-75%, or 50%-90% reduction in the size of at least one tumor in the patient.

[0043] When the cancer to be treated is a brain metastases, the method may be further characterized according to the reduction in number and/or size of the brain metastases. In certain embodiments, there is at least a 20% reduction in the number of brain metastases in the patient. In certain other embodiments, there is at least a 35% reduction in the number of brain metastases in the patient. In yet other embodiments, there is at least a 50% reduction in the number of brain metastases in the patient. In certain other embodiments, there is at least a 60%, 70%, 80% or 90% reduction in the number of brain metastases in the patient. In certain other embodiments, there is about a 5%-50%, 10%-50%, 20%-50%, 5%-75%, 10%-75%, 20%-75%, or 50%-90% reduction in the number of brain metastases in the patient.

25 Patients for Treatment

[0044] The therapeutic method may be further characterized according to the patient to be treated. In certain embodiments, the patient is an adult human. In certain other embodiments, the patient is a pediatric human.

[0045] In certain embodiments, the patient does not suffer from anemia or have reduced blood volume. In certain embodiments, the patient has at least 95% of the amount of their average daily blood volume.

Form of ABDNAZ

5 **[0046]** In certain embodiments, the patient may be administered a pharmaceutically acceptable salt of ABDNAZ.

III. EXEMPLARY MORE SPECIFIC ABDNAZ FORMULATIONS

[0047] One exemplary more specific formulation is an intravenous formulation containing ABDNAZ for intravenous administration to a patient, comprising:

10 a. whole blood in an amount of at least 60% v/v of the formulation;

b. a polyethylene glycol at a concentration of from about 0.4 μ L/mL to about 30 μ L/mL in the formulation;

c. N,N-dimethylacetamide at a concentration of from about 0.2 μ L/mL to about 15 μ L/mL in the formulation;

15 d. ABDNAZ at a concentration of at least 10 μ g/mL in the formulation;

e. water; and

f. an anticoagulant.

[0048] Another exemplary more specific formulation is a formulation that consists essentially of:

20 a. whole blood in an amount of at least 60% v/v of the formulation;

b. a polyethylene glycol at a concentration of from about 0.4 μ L/mL to about 30 μ L/mL in the formulation;

c. N,N-dimethylacetamide at a concentration of from about 0.2 μ L/mL to about 15 μ L/mL in the formulation;

25 d. ABDNAZ at a concentration of at least 10 μ g/mL in the formulation;

e. water; and

f. an anticoagulant.

[0049] Another exemplary more specific formulation is a formulation that consists of:

- a. whole blood in an amount of at least 60% v/v of the formulation;
- b. a polyethylene glycol at a concentration of from about 0.4 μ L/mL to about 30 μ L/mL in the formulation;
- c. N,N-dimethylacetamide at a concentration of from about 0.2 μ L/mL to about 15 μ L/mL in the formulation;
- d. ABDNAZ at a concentration of at least 10 μ g/mL in the formulation;
- e. water; and
- f. an anticoagulant.

5 **[0050]** Another exemplary more specific formulation is an intravenous formulation containing ABDNAZ for intravenous administration to a patient, comprising:

- a. a blood product (e.g., an erythrocyte cell, blood plasma, or whole blood) in an amount of at least 30% v/v of the formulation;
- b. optionally a polyethylene glycol at a concentration of from about 0.4 μ L/mL to about 30 μ L/mL in the formulation;
- c. optionally N,N-dimethylacetamide at a concentration of from about 0.2 μ L/mL to about 15 μ L/mL in the formulation;
- d. ABDNAZ at a concentration of at least 10 μ g/mL in the formulation;
- e. optionally water; and
- f. optionally an anticoagulant.

10 **[0051]** Another exemplary more specific formulation is an intravenous formulation containing ABDNAZ for intravenous administration to a patient, comprising:

- a. whole blood in an amount of at least 30% v/v of the formulation;
- b. a polyethylene glycol (e.g., at a concentration of from about 0.4 μ L/mL to about 30 μ L/mL in the formulation);
- c. N,N-dimethylacetamide (e.g., at a concentration of from about 0.2 μ L/mL to about 15 μ L/mL in the formulation);

- d. ABDNAZ at a concentration of at least 10 $\mu\text{g}/\text{mL}$ in the formulation;
- e. water; and
- f. an anticoagulant.

[0052] Another exemplary more specific formulation is a formulation that consists essentially

5 of:

- a. whole blood in an amount of at least 30% v/v of the formulation;
- b. a polyethylene glycol (e.g., at a concentration of from about 0.4 $\mu\text{L}/\text{mL}$ to about 30 $\mu\text{L}/\text{mL}$ in the formulation);
- c. N,N-dimethylacetamide (e.g., at a concentration of from about 0.2 $\mu\text{L}/\text{mL}$ to about 15 $\mu\text{L}/\text{mL}$ in the formulation);
- d. ABDNAZ at a concentration of at least 10 $\mu\text{g}/\text{mL}$ in the formulation;
- e. water; and
- f. an anticoagulant.

Exemplary Features of Intravenous Formulation

15 **[0053]** The intravenous formulation may be characterized according to, for example, the identity of a polyethylene glycol, anticoagulant, concentration of ABDNAZ, amount of whole blood and other features described herein below.

Polyethylene Glycol

[0054] The formulation may be further characterized according to the identity of a 20 polyethylene glycol in the ABDNAZ formulation. Accordingly, in certain embodiments, the polyethylene glycol is a polyethylene glycol having a number-average molecular weight in the range of about 200 g/mol to about 600 g/mol. In certain embodiments, the polyethylene glycol is a polyethylene glycol having a number-average molecular weight of about 400 g/mol.

[0055] In certain embodiments, the polyethylene glycol is present at a concentration of from 25 about 0.4 $\mu\text{L}/\text{mL}$ to about 4 $\mu\text{L}/\text{mL}$ in the formulation. In certain embodiments, the N,N-dimethylacetamide at a concentration of from about 0.2 $\mu\text{L}/\text{mL}$ to about 2 $\mu\text{L}/\text{mL}$ in the formulation.

Anticoagulant

[0056] The formulation may be further characterized according to the identity of an anticoagulant in the ABDNAZ formulation. Accordingly, in certain embodiments, the anticoagulant comprises one or more of heparin and a citrate salt. In certain embodiments, the 5 anticoagulant is a solution comprising an alkali metal citrate salt, dextrose, and water.

Concentration of ABDNAZ

[0057] The formulation may be further characterized according to the concentration of ABDNAZ in the ABDNAZ formulation. Accordingly, in certain embodiments, the ABDNAZ formulation contains ABDNAZ at a concentration of at least 20 $\mu\text{g}/\text{mL}$. In certain embodiments, 10 the ABDNAZ formulation contains ABDNAZ at a concentration of at least 50 $\mu\text{g}/\text{mL}$. In certain embodiments, the ABDNAZ formulation contains ABDNAZ at a concentration of at least 100 $\mu\text{g}/\text{mL}$. In certain embodiments, the ABDNAZ formulation contains ABDNAZ at a concentration of at least 150 $\mu\text{g}/\text{mL}$. In certain embodiments, the ABDNAZ formulation contains ABDNAZ at a concentration in the range of about 10 $\mu\text{g}/\text{mL}$ to about 1 mg/mL. In certain embodiments, the 15 ABDNAZ formulation contains ABDNAZ at a concentration in the range of about 10 $\mu\text{g}/\text{mL}$ to about 0.5 mg/mL. In certain embodiments, the ABDNAZ formulation contains ABDNAZ at a concentration in the range of about 10 $\mu\text{g}/\text{mL}$ to about 250 $\mu\text{g}/\text{mL}$. In certain embodiments, the ABDNAZ formulation contains ABDNAZ at a concentration in the range of about 20 $\mu\text{g}/\text{mL}$ to about 200 $\mu\text{g}/\text{mL}$.

20 Amount of Whole Blood

[0058] The formulation may be further characterized according to the amount of whole blood in the ABDNAZ formulation. Accordingly, in certain embodiments, the whole blood constitutes at least 30% wt/wt of the formulation. In certain embodiments, the whole blood constitutes at least 40% wt/wt of the formulation. In certain embodiments, the whole blood constitutes at least 50% 25 wt/wt of the formulation. In certain embodiments, the whole blood constitutes at least 75% wt/wt of the formulation. In certain embodiments, the whole blood constitutes at least 90% wt/wt of the formulation. In certain embodiments, the whole blood constitutes from about 60% wt/wt to about

99% wt/wt of the formulation. In certain embodiments, the whole blood constitutes from about 70% wt/wt to about 95% wt/wt of the formulation. In certain embodiments, the whole blood constitutes from about 75% wt/wt to about 90% wt/wt of the formulation. In certain embodiments, there is from about 90 mL to about 110 mL of whole blood in the formulation. In certain 5 embodiments, wherein there is from about 95 mL to about 105 mL of whole blood in the formulation. In certain embodiments, there is about 100 mL of whole blood in the formulation.

Unit Dose Form of Intravenous Formulation

[0059] The formulation may be further characterized according to the volume of a unit dose of the ABDNAZ formulation. Accordingly, in certain embodiments, the formulation is in the form of 10 a unit dose having a volume in the range of about 10 mL to about 200 mL. In certain embodiments, the formulation is in the form of a unit dose having a volume in the range of about 10 mL to about 15 mL, about 15 mL to about 20 mL, about 20 mL to about 30 mL, about 30 mL to about 40 mL, or about 40 mL to about 50 mL. In certain embodiments, the formulation is in the form of a unit dose having a volume in the range of about 50 mL to about 200 mL. In certain 15 embodiments, the formulation is in the form of a unit dose having a volume in the range of about 75 mL to about 150 mL. In certain embodiments, the formulation is in the form of a unit dose having a volume in the range of about 90 mL to about 140 mL. In certain embodiments, the formulation is in the form of a unit dose having a volume in the range of about 100 mL to about 140 mL. In certain embodiments, the formulation is in the form of a unit dose having a volume in the range of about 100 mL to about 120 mL.

Characterization of Pain Effect Upon Intravenous Administration to Patient

[0060] The formulation may be further characterized according to the extent of pain experienced by the patient upon intravenous administration of the ABDNAZ formulation to the patient. Accordingly, in certain embodiments, the formulation is characterized by the feature that 25 any pain experienced by the patient at the site of intravenous administration due to intravenous administration of the formulation to the patient at a rate in the range of 10 mL/hour to 50 mL/hour is no greater than Grade 2. In certain embodiments, wherein the formulation is characterized by the feature that any pain experienced by the patient at the site of intravenous administration due to

intravenous administration of the formulation to the patient at a rate in the range of 10 mL/hour to 50 mL/hour is no greater than Grade 1.

[0061] The description above describes multiple aspects and embodiments of the invention. The patent application specifically contemplates all combinations and permutations of the aspects and embodiments.

IV. KITS FOR USE IN MEDICAL APPLICATIONS

[0062] Another aspect of the invention provides a kit for intravenous administration of an ABDNAZ formulation to a patient suffering from cancer in order to treat the cancer. The kit comprises: (i) a formulation comprising ABDNAZ, and (ii) instructions for intravenous administration of an ABDNAZ formulation to a patient suffering from cancer in order to treat the cancer according to procedures described herein.

[0063] Still another aspect of the invention provides a kit for rapid intravenous administration of an ABDNAZ formulation to a patient while minimizing injection site pain experienced by the patient. The kit comprises: (i) a formulation comprising ABDNAZ, and (ii) instructions for rapid intravenous administration of an ABDNAZ formulation to a patient while minimizing injection site pain experienced by the patient according to procedures described herein.

V. DEFINITIONS

[0064] To facilitate an understanding of the present invention, a number of terms and phrases are defined below.

[0065] The terms “a” and “an” as used herein mean “one or more” and include the plural unless the context is inappropriate.

[0066] As used herein, the term “patient” refers to organisms to be treated by the methods of the present invention. Such organisms are preferably mammals (*e.g.*, murines, simians, equines, bovines, porcines, canines, felines, and the like), and more preferably humans.

[0067] As used herein, the term “effective amount” refers to the amount of a compound (*e.g.*, a compound of the present invention) sufficient to effect beneficial or desired results. An effective

amount can be administered in one or more administrations, applications or dosages and is not intended to be limited to a particular formulation or administration route.

[0068] As used herein, the term “treating” includes any effect, *e.g.*, lessening, reducing, modulating, ameliorating or eliminating, that results in the improvement of the condition, disease, disorder, and the like, or ameliorating a symptom thereof.

[0069] As used herein, the terms “alleviate” and “alleviating” refer to reducing the severity of the condition, such as reducing the severity by, for example, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%.

[0070] As used herein, the term “pharmaceutical composition” refers to the combination of an active agent with a carrier, inert or active, making the composition especially suitable for diagnostic or therapeutic use *in vivo* or *ex vivo*.

[0071] As used herein, the term “pharmaceutically acceptable carrier” refers to any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, emulsions (*e.g.*, such as an oil/water or water/oil emulsions), and various types of wetting agents. The compositions also can include stabilizers and preservatives. For examples of carriers, stabilizers and adjuvants, see, for example, Martin, Remington's Pharmaceutical Sciences, 15th Ed., Mack Publ. Co., Easton, PA [1975].

[0072] As used herein, the term “pharmaceutically acceptable salt” refers to any pharmaceutically acceptable salt (*e.g.*, acid or base) of a compound of the present invention which, upon administration to a subject, is capable of providing a compound of this invention or an active metabolite or residue thereof. As is known to those of skill in the art, “salts” of the compounds of the present invention may be derived from inorganic or organic acids and bases. Examples of acids include, but are not limited to, hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salicylic, succinic, toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic, ethanesulfonic, formic, benzoic, malonic, naphthalene-2-sulfonic, benzenesulfonic acid, and the like. Other acids, such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates

in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.

[0073] Examples of bases include, but are not limited to, alkali metal (e.g., sodium) hydroxides, alkaline earth metal (e.g., magnesium) hydroxides, ammonia, and compounds of formula NW_4^+ , wherein W is C_{1-4} alkyl, and the like.

[0074] Examples of salts include, but are not limited to: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, flucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, palmoate, pectinate, persulfate, phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, undecanoate, and the like. Other examples of salts include anions of the compounds of the present invention compounded with a suitable cation such as Na^+ , NH_4^+ , and NW_4^+ (wherein W is a C_{1-4} alkyl group), and the like.

[0075] For therapeutic use, salts of the compounds of the present invention are contemplated as being pharmaceutically acceptable. However, salts of acids and bases that are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound.

[0076] The term “about” as used herein when referring to a measurable value (e.g., weight, time, and dose) is meant to encompass variations, such as $\pm 10\%$, $\pm 5\%$, $\pm 1\%$, or $\pm 0.1\%$ of the specified value.

[0077] Throughout the description, where compositions are described as having, including, or comprising specific components, or where processes and methods are described as having, including, or comprising specific steps, it is contemplated that, additionally, there are compositions of the present invention that consist essentially of, or consist of, the recited components, and that there are processes and methods according to the present invention that consist essentially of, or consist of, the recited processing steps.

[0078] As a general matter, compositions specifying a percentage are by weight unless otherwise specified. Further, if a variable is not accompanied by a definition, then the previous definition of the variable controls.

EXAMPLES

[0079] The invention now being generally described, will be more readily understood by 5 reference to the following examples, which are included merely for purposes of illustration of certain aspects and embodiments of the present invention, and are not intended to limit the invention.

EXAMPLE 1 – INTRAVENOUS ADMINISTRATION OF AN ABDNAZ FORMULATION FORMED BY COMBINING WHOLE BLOOD, ABDNAZ, AND AN ANTICOAGULANT

[0080] As part of a clinical trial, twelve, adult human patients were intravenously administered 10 an ABDNAZ formulation formed by combining whole blood, ABDNAZ (4 mg), an anticoagulant, and certain other materials as described in more detail below. Intravenous administration of the ABDNAZ formulation was performed at an initial flow rate of 5 mL/minute. The procedure permitted an increase in the flow rate if tolerable to the patient. No patients reported experiencing 15 pain at the injection site. Further description of experimental procedures and results are provided below.

Part I – Experimental Procedures

[0081] As part of a clinical trial, twelve, adult human patients were intravenously administered an ABDNAZ formulation. The intravenous administration was central venous 20 administration. The ABDNAZ formulation was prepared as follows:

- (1) Approximately 100 mL of the patient's blood ass drawn and then combined with an 11 mL aliquot of ACD-A solution (which is an anticoagulant solution containing sodium citrate, such as that commercially available from Citra Labs) to produce Solution No. 1;
- (2) Solution No. 1 was mixed with 4 mL of a solution containing ABDNAZ (4 mg), polyethylene glycol having a number average molecular weight of 400 g/mol (6% w/w), dimethylacetamide (3 % w/w), and water for injection, to produce the ABDNAZ formulation.

[0082] The ABDNAZ formulation was passed through a sterile filter and intravenously administered to the patient at an initial flow rate of 5 mL/minute. The flow rate could be increased if tolerable to the patient. At an infusion rate of 5 mL/minute, the ABDNAZ formulation having a volume of 115 mL can be intravenously administered in about 23 minutes.

5 Part II – Results

[0083] No patients reported experiencing pain at the injection site.

EXAMPLE 2 – INTRAVENOUS ADMINISTRATION OF AN ABDNAZ FORMULATION CONTAINING ABDNAZ, PEG-400, DIMETHYLACETAMIDE, AND WATER

[0084] An aqueous solution of ABDNAZ was intravenously administered to twenty-five human patients as part of a Phase I clinical study. The aqueous solution contained ABDNAZ (2 mg/mL), polyethylene glycol having a number average molecular weight of 400 g/mol (6% w/w), dimethylacetamide (3 % w/w), and water for injection. Patients were administered a volume of the aqueous solution of ABDNAZ sufficient to deliver a dose of ABDNAZ in the amount of 10 mg/m², 16.7 mg/m², 24.6 mg/m², 33 mg/m², 55 mg/m², or 83 mg/m². Pain at the injection site due to administration of the aqueous solution of ABDNAZ was experienced by 84% of patients. The first patient to receive the aqueous solution of ABDNAZ by central intravenous administration over a period of 20 minutes to deliver a 10 mg/m² dose of ABDNAZ experienced infusion-site pain and nasopharyngeal burning sensation of such high intensity that the patient voluntarily withdrew from the study. Thereafter, peripheral intravenous delivery in the antecubital or forearm area was used and a longer duration of time was used to perform the infusion (e.g., ranging from 2 hours to 8 hours, while administering at a rate of 3.5 mL/hour that could be adjusted up or down in 0.5 mL/hour increments based on patients' ability to tolerate the infusion). Further description of experimental procedures and results are provided below.

Part I – Experimental Procedures

[0085] In this open-label, human, dose-escalation phase 1 study, a 3+3 dose-escalation design was used to assess safety, tolerability, and pharmacokinetics of ABDNAZ. Patients were enrolled from the University of California–San Diego Moores Cancer Center, La Jolla, CA, USA, and the Sarah Cannon Research Institute, Nashville, TN, USA. Eligible patients were 18 years or older with histologically confirmed advanced solid tumours for which standard curative treatment did

not exist. All patients had an Eastern Cooperative Group performance status of 2 or less, an estimated life expectancy of at least 12 weeks, and adequate laboratory parameters (absolute neutrophil count $\geq 1.5 \times 10^6$ cells per L, platelet count $\geq 7.5 \times 10^6$ cells per L, haemoglobin ≥ 90 g/L, serum total bilirubin ≤ 427.5 μ mol/L, aspartate amino transferase and alanine aminotransferase 5 concentration ≤ 2.5 times the upper normal limit [ULN; < 5 times the ULN for hepatic involvement], and creatinine clearance > 50 mL per min). Previous antineoplastic therapies had to have been discontinued at least 6 weeks before intervention start, and patients could show no residual side-effects of previous therapies. Patients were required to practice effective contraception while receiving ABDNAZ. All patients had evaluable disease. Key exclusion 10 criteria included hypoalbuminaemia (albumin < 30 g/L), active brain metastases (although patients with stable brain metastases were eligible), pregnancy or breast feeding, any other clinically significant illness or psychiatric disorder that could affect compliance or endpoint assessments, and concurrent use of any other investigational drugs.

[0086] Screening assessments were done at the clinical site less than 16 days before treatment 15 initiation and included an electrocardiogram, urinalysis, Modified Borg Dyspnea Assessment, pulse oximetry, and radiographic tumour measurement. A medical history, physical examination, pregnancy test, performance status, complete blood count, a comprehensive serum chemistry, and urinalysis were done within 16 days of the first dosing.

[0087] The protocol was reviewed and approved by the investigational review boards at the 20 Moores Cancer Center and the Sarah Cannon Research Institute. All procedures were performed in accordance with the principles established by the Helsinki Declaration. Patients gave written informed consent for all clinical and research aspects of the study before enrolment, which was done according to national and institutional guidelines.

[0088] An aqueous solution of ABDNAZ was intravenously administered to patients. The 25 aqueous solution contained ABDNAZ (2 mg/mL), polyethylene glycol having a number average molecular weight of 400 g/mol (6% w/w), dimethylacetamide (3 % w/w), and water for injection. Patients were administered a volume of the aqueous solution of ABDNAZ sufficient to deliver a dose of ABDNAZ in the amount of 10 mg/m², 16.7 mg/m², 24.6 mg/m², 33 mg/m², 55 mg/m², or 83 mg/m². Three patients were given a starting dose of 10 mg/m² of ABDNAZ before dose

escalation (to 16.7 mg/m², 24.6 mg/m², 33 mg/m², 55 mg/m², and 83 mg/m²), with at least three patients per dose cohort, allowing a 2-week observation period before dose escalation. The duration of infusion was titrated to patient tolerance and varied between dose cohorts and patients. However, for the first patient in the 10 mg/m² dose cohort, the aqueous solution of ABDNAZ was 5 administered centrally over 20 min, and the patient experienced infusion-site pain and nasopharyngeal burning sensation of such high intensity that the patient voluntarily withdrew from the study. Thereafter, peripheral intravenous delivery in the antecubital or forearm area was used and a longer duration of time was used to perform the infusion (e.g., ranging from 2 hours to 8 hours, while administering at a rate of 3.5 mL/hour that could be adjusted up or down in 0.5 10 mL/hour increments based on patients' ability to tolerate the infusion). The peripheral intravenous delivery was better tolerated; most patients showed a prominent dose-dependent vasodilation in the forearm and transient mild-to-moderate pain. For some patients in the highest dose cohort (83 mg/m²), we had to split the total dose and delivery of ABDNAZ into a twice-weekly regimen. Three patients in the highest dose cohort and one patient in the penultimate dose cohort (55 mg/m²) 15 needed a dose reduction to 33 mg/m² because of localized infusion pain.

Part II – Results

[0089] Pain at the injection site, mostly grade 1 and grade 2, was the most common adverse event related to treatment, experienced by 21 (84%) patients. Other common ABDNAZ-related adverse events included arm swelling or oedema (eight [32%] patients), and vein hardening (seven 20 [28%] patients). Time constraints related to management of infusion pain from ABDNAZ resulted in a maximally feasible dose of 83 mg/m². ABDNAZ-related adverse events observed during the study are listed in the table below.

Adverse Event	10 mg/m ² Dose ABDNAZ (n=6)			16.7 mg/m ² Dose ABDNAZ (n=3)			24.6 mg/m ² Dose ABDNAZ (n=3)			33 mg/m ² Dose ABDNAZ (n=4)			55 mg/m ² Dose ABDNAZ (n=3)			83 mg/m ² Dose ABDNAZ (n=6)		
	Grade 1-2	Grade 3	Grade 1-2	Grade 3	Grade 1-2	Grade 3	Grade 1-2	Grade 3	Grade 1-2	Grade 3	Grade 1-2	Grade 3	Grade 1-2	Grade 3	Grade 1-2	Grade 3		
Infusion-site pain	4 (67%)	0	3 (100%)	0	1 (33%)	0	3 (75%)	1 (25%)	3 (100%)	0	6 (100%)	0	6 (100%)	0	6 (100%)	0		
Arm swelling or oedema	0	0	1 (33%)	0	0	0	1 (25%)	0	2 (67%)	0	4 (67%)	0	4 (67%)	0	4 (67%)	0		
Vein hardening	0	0	0	0	0	0	1 (25%)	0	1 (33%)	0	5 (83%)	0	5 (83%)	0	5 (83%)	0		
Dyspnoea or wheezing	1 (17%)	0	0	0	0	0	0	0	1 (33%)	0	3 (50%)	0	3 (50%)	0	3 (50%)	0		
Mouth tingling or burning	0	0	0	0	0	0	0	0	2 (67%)	0	2 (33%)	0	2 (33%)	0	2 (33%)	0		

INCORPORATION BY REFERENCE

[0090] The entire disclosure of each of the patent documents and scientific articles referred to herein is incorporated by reference for all purposes.

EQUIVALENTS

5 **[0091]** The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting the invention described herein. Scope of the invention is thus indicated by the appended claims rather than by the foregoing description, and all changes that come within the meaning and range of equivalency of the claims are intended to be
10 embraced therein.

What is claimed is:

1. 1. A method for intravenous administration of an ABDNAZ formulation to a patient suffering from cancer in order to treat the cancer, comprising intravenously administering to the patient in need thereof a therapeutically effective amount of an ABDNAZ formulation comprising whole blood, ABDNAZ, and an anticoagulant, in order to treat the cancer.
1. 2. The method of claim 1, wherein the whole blood is autologous whole blood.
1. 3. The method of claim 1 or 2, wherein the ABDNAZ formulation is intravenously administered to the patient at a rate of at least 5 mL/hour.
1. 4. The method of claim 1 or 2, wherein the ABDNAZ formulation is intravenously administered to the patient at a rate of at least 10 mL/hour.
1. 5. The method of any one of claims 1-4, wherein the cancer is a solid tumor.
1. 6. The method of any one of claims 1-4, wherein the cancer is brain cancer, bladder cancer, breast cancer, cervical cancer, cholangiocarcinoma, colon cancer, colorectal cancer, endometrial cancer, esophageal cancer, lung cancer, liver cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, renal cancer, stomach cancer, testicular cancer, or uterine cancer.
1. 7. The method of any one of claims 1-4, wherein the cancer is brain cancer.
1. 8. The method of any one of claims 1-4, wherein the cancer is colorectal cancer.
1. 9. The method of any one of claims 1-4, wherein the cancer is cholangiocarcinoma or lung cancer.
1. 10. The method of any one of claims 1-4, wherein the cancer is a leukemia or lymphoma.
1. 11. The method of any one of claims 1-4, wherein the cancer is a B-cell lymphoma or non-Hodgkin lymphoma.

- 1 12. The method of any one of claims 1-11, wherein any pain experienced by the patient at the site
2 of intravenous administration of the ABDNAZ formulation due to intravenous administration
3 of the ABDNAZ formulation is no greater than Grade 2.
- 1 13. The method of any one of claims 1-11, wherein any pain experienced by the patient at the site
2 of intravenous administration of the ABDNAZ formulation due to intravenous administration
3 of the ABDNAZ formulation is no greater than Grade 1.
- 1 14. A method for rapid intravenous administration of an ABDNAZ formulation to a patient while
2 minimizing injection site pain experienced by the patient, comprising intravenously
3 administering to the patient at a rate of at least 10 mL/hour an ABDNAZ formulation
4 comprising whole blood, ABDNAZ, and an anticoagulant, wherein any pain experienced by
5 the patient at the site of intravenous administration of the ABDNAZ formulation due to
6 intravenous administration of the ABDNAZ formulation is no greater than Grade 2.
- 1 15. The method of claim 14, wherein any pain experienced by the patient at the site of intravenous
2 administration of the ABDNAZ formulation due to intravenous administration of the
3 ABDNAZ formulation is no greater than Grade 1.
- 1 16. The method of claim 14 or 15, wherein the patient is suffering from cancer.
- 1 17. The method of claim 16, wherein the cancer is a solid tumor.
- 1 18. The method of claim 16, wherein the cancer is brain cancer, bladder cancer, breast cancer,
2 cervical cancer, cholangiocarcinoma, colon cancer, colorectal cancer, endometrial cancer,
3 esophageal cancer, lung cancer, liver cancer, melanoma, ovarian cancer, pancreatic cancer,
4 prostate cancer, rectal cancer, renal cancer, stomach cancer, testicular cancer, or uterine cancer.
- 1 19. The method of claim 16, wherein the cancer is brain cancer.
- 1 20. The method of claim 16, wherein the cancer is colorectal cancer.
- 1 21. The method of claim 16, wherein the cancer is cholangiocarcinoma or lung cancer.
- 1 22. The method of claim 16, wherein the cancer is a leukemia or lymphoma.

- 1 23. The method of claim 16, wherein the cancer is a B-cell lymphoma or non-Hodgkin lymphoma.
- 1 24. The method of any one of claims 1-23, wherein the ABDNAZ formulation is intravenously
2 administered to the patient at a rate of at least 30 mL/hour.
- 1 25. The method of any one of claims 1-23, wherein the ABDNAZ formulation is intravenously
2 administered to the patient at a rate of at least 60 mL/hour.
- 1 26. The method of any one of claims 1-23, wherein the ABDNAZ formulation is intravenously
2 administered to the patient at a rate of at least 90 mL/hour.
- 1 27. The method of any one of claims 1-23, wherein the ABDNAZ formulation is intravenously
2 administered to the patient at a rate of at least 120 mL/hour.
- 1 28. The method of any one of claims 1-23, wherein the ABDNAZ formulation is intravenously
2 administered to the patient at a rate of at least 200 mL/hour.
- 1 29. The method of any one of claims 1-23, wherein the ABDNAZ formulation is intravenously
2 administered to the patient at a rate of at least 300 mL/hour.
- 1 30. The method of any one of claims 1-29, wherein the ABDNAZ formulation contains ABDNAZ
2 at a concentration of at least 10 μ g/mL.
- 1 31. The method of any one of claims 1-29, wherein the ABDNAZ formulation contains ABDNAZ
2 at a concentration of at least 20 μ g/mL.
- 1 32. The method of any one of claims 1-29, wherein the ABDNAZ formulation contains ABDNAZ
2 at a concentration of at least 50 μ g/mL.
- 1 33. The method of any one of claims 1-29, wherein the ABDNAZ formulation contains ABDNAZ
2 at a concentration of at least 100 μ g/mL.
- 1 34. The method of any one of claims 1-29, wherein the ABDNAZ formulation contains ABDNAZ
2 at a concentration of at least 150 μ g/mL.

- 1 35. The method of any one of claims 1-29, wherein the ABDNAZ formulation contains ABDNAZ
2 at a concentration in the range of about 10 μ g/mL to about 1 mg/mL.
- 1 36. The method of any one of claims 1-29, wherein the ABDNAZ formulation contains ABDNAZ
2 at a concentration in the range of about 10 μ g/mL to about 0.5 mg/mL.
- 1 37. The method of any one of claims 1-29, wherein the ABDNAZ formulation contains ABDNAZ
2 at a concentration in the range of about 10 μ g/mL to about 250 μ g/mL.
- 1 38. The method of any one of claims 1-29, wherein the ABDNAZ formulation contains ABDNAZ
2 at a concentration in the range of about 20 μ g/mL to about 200 μ g/mL.
- 1 39. The method of any one of claims 1-38, wherein the ABDNAZ formulation consists essentially
2 of whole blood, ABDNAZ, and an anticoagulant.
- 1 40. The method of any one of claims 1-38, wherein the ABDNAZ formulation consists of whole
2 blood, ABDNAZ, an anticoagulant, and optionally one or more of water, a polyethylene glycol,
3 and N,N-dimethylacetamide.
- 1 41. The method of any one of claims 1-38, wherein the ABDNAZ formulation consists of whole
2 blood, ABDNAZ, an anticoagulant, and optionally one or more of water, a polyethylene glycol
3 having a number average molecular weight in the range of about 200 g/mol to about 600 g/mol,
4 and N,N-dimethylacetamide.
- 1 42. The method of any one of claims 1-38, wherein the ABDNAZ formulation consists of whole
2 blood, ABDNAZ, an anticoagulant, water, a polyethylene glycol having a number average
3 molecular weight in the range of about 200 g/mol to about 600 g/mol, and N,N-
4 dimethylacetamide.
- 1 43. The method of any one of claims 1-38, wherein the ABDNAZ formulation consists of whole
2 blood, ABDNAZ, an anticoagulant, and optionally one or more of water, a polyethylene glycol
3 having a number average molecular weight of about 400 g/mol, and N,N-dimethylacetamide.

- 1 44. The method of any one of claims 1-38, wherein the ABDNAZ formulation consists of whole
- 2 blood, ABDNAZ, an anticoagulant, water, a polyethylene glycol having a number average
- 3 molecular weight of about 400 g/mol, and N,N-dimethylacetamide.
- 1 45. The method of any one of claims 1-44, wherein the anticoagulant comprises one or more of
- 2 heparin and a citrate salt.
- 1 46. The method of any one of claims 1-44, wherein the anticoagulant is a solution comprising an
- 2 alkali metal citrate salt, dextrose, and water.
- 1 47. The method of any one of claims 1-46, wherein the anticoagulant is present in the ABDNAZ
- 2 formulation in an amount ranging from about 0.1% wt/wt to about 15% w/w.
- 1 48. The method of any one of claims 1-47, wherein the whole blood constitutes at least 30% wt/wt
- 2 of the ABDNAZ formulation.
- 1 49. The method of any one of claims 1-47, wherein the whole blood constitutes at least 60% wt/wt
- 2 of the ABDNAZ formulation.
- 1 50. The method of any one of claims 1-47, wherein the whole blood constitutes at least 75% wt/wt
- 2 of the ABDNAZ formulation.
- 1 51. The method of any one of claims 1-47, wherein the whole blood constitutes at least 90% wt/wt
- 2 of the ABDNAZ formulation.
- 1 52. The method of any one of claims 1-47, wherein the whole blood constitutes from about 60%
- 2 wt/wt to about 99% wt/wt of the ABDNAZ formulation.
- 1 53. The method of any one of claims 1-47, wherein the whole blood constitutes from about 70%
- 2 wt/wt to about 95% wt/wt of the ABDNAZ formulation.
- 1 54. The method of any one of claims 1-47, wherein the whole blood constitutes from about 75%
- 2 wt/wt to about 90% wt/wt of the ABDNAZ formulation.

- 1 55. The method of any one of claims 1-54, wherein there is from about 90 mL to about 110 mL of
2 whole blood in the ABDNAZ formulation.
- 1 56. The method of any one of claims 1-54, wherein there is from about 95 mL to about 105 mL of
2 whole blood in the ABDNAZ formulation.
- 1 57. The method of any one of claims 1-54, wherein there is about 100 mL of whole blood in the
2 ABDNAZ formulation.
- 1 58. The method of any one of claims 1-54, wherein there is about 10 mL to about 20 mL of whole
2 blood in the ABDNAZ formulation.
- 1 59. The method of any one of claims 1-54, wherein there is about 10 mL of whole blood in the
2 ABDNAZ formulation.
- 1 60. The method of any one of claims 1-59, wherein the ABDNAZ formulation has a volume in the
2 range of about 50 mL to about 200 mL.
- 1 61. The method of any one of claims 1-59, wherein the ABDNAZ formulation has a volume in the
2 range of about 75 mL to about 150 mL.
- 1 62. The method of any one of claims 1-59, wherein the ABDNAZ formulation has a volume in the
2 range of about 90 mL to about 140 mL.
- 1 63. The method of any one of claims 1-59, wherein the ABDNAZ formulation has a volume in the
2 range of about 100 mL to about 140 mL.
- 1 64. The method of any one of claims 1-59, wherein the ABDNAZ formulation has a volume in the
2 range of about 100 mL to about 120 mL.
- 1 65. The method of any one of claims 1-59, wherein the ABDNAZ formulation has a volume in the
2 range of about 10 mL to about 20 mL.
- 1 66. The method of any one of claims 1-65, wherein intravenous administration of the ABDNAZ
2 formulation commences within about 1 hour after formation of the ABDNAZ formulation.

- 1 67. The method of any one of claims 1-65, wherein intravenous administration of the ABDNAZ
2 formulation commences within about 30 minutes after formation of the ABDNAZ formulation.
- 1 68. The method of any one of claims 1-65, wherein intravenous administration of the ABDNAZ
2 formulation commences within about 20 minutes after formation of the ABDNAZ formulation.
- 1 69. The method of any one of claims 1-68, wherein intravenous administration of the ABDNAZ
2 formulation is complete within about 6 hours after formation of the ABDNAZ formulation.
- 1 70. The method of any one of claims 1-68, wherein intravenous administration of the ABDNAZ
2 formulation is complete within about 4 hours after formation of the ABDNAZ formulation.
- 1 71. The method of any one of claims 1-70, further comprising obtaining an aliquot of whole blood
2 from the patient, and then using said aliquot to prepare the ABDNAZ formulation for
3 administration to the patient.
- 1 72. The method of any one of claims 1-71, wherein the intravenous administration is central
2 intravenous administration.
- 1 73. The method of any one of claims 1-71, wherein the intravenous administration is peripheral
2 intravenous administration.
- 1 74. The method of any one of claims 1-73, wherein the patient is an adult human.
- 1 75. The method of any one of claims 1-73, wherein the patient is a pediatric human.
- 1 76. The method of any one of claims 1-75, wherein the patient does not suffer from anemia or have
2 reduced blood volume.
- 1 77. The method of any one of claims 1-75, wherein the patient has at least 95% of the amount of
2 their average daily blood volume.
- 1 78. An intravenous formulation containing ABDNAZ for intravenous administration to a patient,
2 comprising:
 - 3 a. whole blood in an amount of at least 60% v/v of the formulation;

- 4 b. a polyethylene glycol at a concentration of from about 0.4 μ L/mL to about 30
5 μ L/mL in the formulation;
- 6 c. N,N-dimethylacetamide at a concentration of from about 0.2 μ L/mL to about 15
7 μ L/mL in the formulation;
- 8 d. ABDNAZ at a concentration of at least 10 μ g/mL in the formulation;
- 9 e. water; and
- 10 f. an anticoagulant.

1 79. The intravenous formulation of claim 78, wherein the formulation consists essentially of:

- 2 a. whole blood in an amount of at least 60% v/v of the formulation;
- 3 b. a polyethylene glycol at a concentration of from about 0.4 μ L/mL to about 30
4 μ L/mL in the formulation;
- 5 c. N,N-dimethylacetamide at a concentration of from about 0.2 μ L/mL to about 15
6 μ L/mL in the formulation;
- 7 d. ABDNAZ at a concentration of at least 10 μ g/mL in the formulation;
- 8 e. water; and
- 9 f. an anticoagulant.

1 80. The intravenous formulation of claim 78, wherein the formulation consists of:

- 2 a. whole blood in an amount of at least 60% v/v of the formulation;
- 3 b. a polyethylene glycol at a concentration of from about 0.4 μ L/mL to about 30
4 μ L/mL in the formulation;
- 5 c. N,N-dimethylacetamide at a concentration of from about 0.2 μ L/mL to about 15
6 μ L/mL in the formulation;
- 7 d. ABDNAZ at a concentration of at least 10 μ g/mL in the formulation;
- 8 e. water; and
- 9 f. an anticoagulant.

1 81. The intravenous formulation of any one of claims 78-81, wherein the polyethylene glycol is a
2 polyethylene glycol having a number average molecular weight in the range of about 200
3 g/mol to about 600 g/mol.

- 1 82. The intravenous formulation of any one of claims 78-81, wherein the polyethylene glycol is a
2 polyethylene glycol having a number average molecular weight of about 400 g/mol.
- 1 83. The intravenous formulation of any one of claims 78-82, wherein the anticoagulant comprises
2 one or more of heparin and a citrate salt.
- 1 84. The intravenous formulation of any one of claims 78-82, wherein the anticoagulant is a
2 solution comprising an alkali metal citrate salt, dextrose, and water.
- 1 85. The intravenous formulation of any one of claims 78-84, wherein the ABDNAZ formulation
2 contains ABDNAZ at a concentration of at least 20 $\mu\text{g}/\text{mL}$.
- 1 86. The intravenous formulation of any one of claims 78-84, wherein the ABDNAZ formulation
2 contains ABDNAZ at a concentration of at least 50 $\mu\text{g}/\text{mL}$.
- 1 87. The intravenous formulation of any one of claims 78-84, wherein the ABDNAZ formulation
2 contains ABDNAZ at a concentration of at least 100 $\mu\text{g}/\text{mL}$.
- 1 88. The intravenous formulation of any one of claims 78-84, wherein the ABDNAZ formulation
2 contains ABDNAZ at a concentration of at least 150 $\mu\text{g}/\text{mL}$.
- 1 89. The intravenous formulation of any one of claims 78-84, wherein the ABDNAZ formulation
2 contains ABDNAZ at a concentration in the range of about 10 $\mu\text{g}/\text{mL}$ to about 1 mg/mL .
- 1 90. The intravenous formulation of any one of claims 78-84, wherein the ABDNAZ formulation
2 contains ABDNAZ at a concentration in the range of about 10 $\mu\text{g}/\text{mL}$ to about 0.5 mg/mL .
- 1 91. The intravenous formulation of any one of claims 78-84, wherein the ABDNAZ formulation
2 contains ABDNAZ at a concentration in the range of about 10 $\mu\text{g}/\text{mL}$ to about 250 $\mu\text{g}/\text{mL}$.
- 1 92. The intravenous formulation of any one of claims 78-84, wherein the ABDNAZ formulation
2 contains ABDNAZ at a concentration in the range of about 20 $\mu\text{g}/\text{mL}$ to about 200 $\mu\text{g}/\text{mL}$.
- 1 93. The intravenous formulation of any one of claims 78-92, wherein the whole blood constitutes
2 at least 60% wt/wt of the formulation.

- 1 94. The intravenous formulation of any one of claims 78-92, wherein the whole blood constitutes
2 at least 75% wt/wt of the formulation.
- 1 95. The intravenous formulation of any one of claims 78-92, wherein the whole blood constitutes
2 at least 90% wt/wt of the formulation.
- 1 96. The intravenous formulation of any one of claims 78-92, wherein the whole blood constitutes
2 from about 60% wt/wt to about 99% wt/wt of the formulation.
- 1 97. The intravenous formulation of any one of claims 78-92, wherein the whole blood constitutes
2 from about 70% wt/wt to about 95% wt/wt of the formulation.
- 1 98. The intravenous formulation of any one of claims 78-92, wherein the whole blood constitutes
2 from about 75% wt/wt to about 90% wt/wt of the formulation.
- 1 99. The intravenous formulation of any one of claims 78-98, wherein there is from about 90 mL to
2 about 110 mL of whole blood in the formulation.
- 1 100. The intravenous formulation of any one of claims 78-98, wherein there is from about 95
2 mL to about 105 mL of whole blood in the formulation.
- 1 101. The intravenous formulation of any one of claims 78-98, wherein there is about 100 mL of
2 whole blood in the formulation.
- 1 102. The intravenous formulation of any one of claims 78-98, wherein there is about 10 mL to
2 about 20 mL of whole blood in the formulation.
- 1 103. The intravenous formulation of any one of claims 78-102, wherein the formulation is in the
2 form of a unit dose having a volume in the range of about 50 mL to about 200 mL.
- 1 104. The intravenous formulation of any one of claims 78-102, wherein the formulation is in the
2 form of a unit dose having a volume in the range of about 75 mL to about 150 mL.
- 1 105. The intravenous formulation of any one of claims 78-102, wherein the formulation is in the
2 form of a unit dose having a volume in the range of about 90 mL to about 140 mL.

- 1 106. The intravenous formulation of any one of claims 78-102, wherein the formulation is in the
- 2 form of a unit dose having a volume in the range of about 100 mL to about 140 mL.
- 1 107. The intravenous formulation of any one of claims 78-102, wherein the formulation is in the
- 2 form of a unit dose having a volume in the range of about 100 mL to about 120 mL.
- 1 108. The intravenous formulation of any one of claims 78-102, wherein the formulation is in the
- 2 form of a unit dose having a volume in the range of about 10 mL to about 30 mL.
- 1 109. The intravenous formulation of any one of claims 78-108, wherein the polyethylene glycol
- 2 is present at a concentration of from about 0.4 μ L/mL to about 4 μ L/mL in the formulation.
- 1 110. The intravenous formulation of any one of claims 78-108, wherein the N,N-
- 2 dimethylacetamide at a concentration of from about 0.2 μ L/mL to about 2 μ L/mL in the
- 3 formulation.
- 1 111. The intravenous formulation of any one of claims 78-110, wherein the formulation is
- 2 characterized by the feature that any pain experienced by the patient at the site of intravenous
- 3 administration due to intravenous administration of the formulation to the patient at a rate in
- 4 the range of 10 mL/hour to 50 mL/hour is no greater than Grade 2.
- 1 112. The intravenous formulation of any one of claims 78-111, wherein the formulation is
- 2 characterized by the feature that any pain experienced by the patient at the site of intravenous
- 3 administration due to intravenous administration of the formulation to the patient at a rate in
- 4 the range of 10 mL/hour to 50 mL/hour is no greater than Grade 1.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2017/012948

A. CLASSIFICATION OF SUBJECT MATTER

A61K 31/397 (2006.01) A61K 9/08 (2006.01) A61K 35/14 (2015.01) A61P 35/00 (2006.01)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPOQUE: *Databases:* EPODOC, WPIAP, TXTE**STN:** *Databases:* REGISTRY, HCAPLUS, MEDLINE, BIOSIS**Internet Search Engines:** Espacenet, Google Scholar, Google, ClinicalTrials.gov**Keywords:** RRX-001, ABDNAZ, blood, anticoagulant, intravenous, formulations, in addition to plurals, synonyms, and other like terms

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	Documents are listed in the continuation of Box C	

 Further documents are listed in the continuation of Box C See patent family annex

* Special categories of cited documents:		
"A" document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search
28 March 2017Date of mailing of the international search report
28 March 2017

Name and mailing address of the ISA/AU

AUSTRALIAN PATENT OFFICE
PO BOX 200, WODEN ACT 2606, AUSTRALIA
Email address: pct@ipaustralia.gov.au

Authorised officer

Andrew Stevens
AUSTRALIAN PATENT OFFICE
(ISO 9001 Quality Certified Service)
Telephone No. 0262256159

INTERNATIONAL SEARCH REPORT		International application No.
C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		PCT/US2017/012948
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2014/0308260 A1 (RadioRx, Inc) 16 October 2014 Whole Document	
A	Fitch <i>et al</i> , Abstract WRM 267, "High resolution MS proves that the developmental cancer drug, RRx-001, alkylates the hemoglobin beta chain", 44th Western Regional Meeting of the American Chemical Society, 3-6 October 2013, Available from the Internet, <URL: http://acswww.org/wrm2013/files/Abstracts_SaturdayAM.pdf >, Last Retrieved 21 March 2017 Whole Document	
A	Scicinski <i>et al</i> , "Preclinical Evaluation of the Metabolism and Disposition of RRx-001, a Novel Investigative Anticancer Agent", <i>Drug Metabolism and Disposition</i> (2012), Vol. 40, No. 9, Pages 1810-1816 Whole Document	
A	View of NCT02489903 on 2015_07_02, "An Open-label, Three Stage, Three Arm Pilot Study of RRx-001 For Second Line or Greater Small Cell Lung Cancer, Third Line or Greater Non-Small Lung Cancer, and Second Line or Greater High Grade Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (TRIPLE THREAT)", Available from the Internet, <URL: https://clinicaltrials.gov/archive/NCT02489903/2015_07_02 >, Published 02 July 2015 according to ClinicalTrials.gov Archive, Last Retrieved 22 March 2017 Whole Document	
P,A	Cabral <i>et al</i> , "A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity?", <i>Medical Oncology</i> (2016), Vol. 33, No. 7, Article Number 63, 7 Pages, doi:10.1007/s12032-016-0775-3, Published 26 May 2016 Whole Document	
P,A	Oronsky <i>et al</i> , "RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials", <i>Expert Opinion on Investigational Drugs</i> (2017), Vol. 26, No. 1, Pages 109-119, Published 21 December 2016 Whole Document	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US2017/012948

This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
US 2014/0308260 A1	16 October 2014	US 2014308260 A1	16 Oct 2014
		WO 2013052803 A2	11 Apr 2013

End of Annex